XML 82 R70.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Interests in subsidiaries (Tables) | 12 Months Ended
--- | ---
Jun. 30, 2018
Text block1 [abstract] |
Summary of interest in subsidiaries | The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 2:
|  |  |  | Ownership interest
Name |  | Principal place of business / Country of incorporation |  | 2018 % |  | 2017 %
Kazia Laboratories Pty Ltd |  | Australia |  | 100% |  | 100%
Kazia Research Pty Ltd |  | Australia |  | 100% |  | 100%
Kazia Therapeutics Inc. |  | United States of America |  | 100% |  | 100%
Glioblast Pty Ltd |  | Australia |  | 100% |  | 100%

X
- Definition The disclosure of subsidiaries. [Refer: Subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2017-01-01 -Paragraph 17 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=27&date=2017-03-01&anchor=para_17_b&doctype=Standard -URIDate 2017-03-09 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2017-01-01 -Paragraph 16 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=27&date=2017-03-01&anchor=para_16_b&doctype=Standard -URIDate 2017-03-09 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2017-01-01 -Paragraph B4 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=12&date=2017-03-01&anchor=para_B4_a&doctype=Appendix&seq=2 -URIDate 2017-03-09 + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Text block. + References No definition available. + Details
Name: | kzia_TextBlock1Abstract
Namespace Prefix: | kzia_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration